M&A / Deals Lilly to acquire CrossBridge Bio for up to $300m Pharmaceutical TechnologyEli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.M&A / DealsRead full story pharminent April 15, 2026 Pharmaceutical Technology Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash. M&A / DealsRead full story Post navigation Previous: Lilly to acquire CrossBridge Bio for up to $300mNext: FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
